As of January 22, 2025, Amylyx Pharmaceuticals (AMLX) has a market cap of $0.30 billion USD. According to our data, Amylyx Pharmaceuticals is ranked No.6702 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.30 B |
-7.94%
|
Dec 31, 2024 | $0.32 B |
-74.32%
|
Dec 29, 2023 | $1.26 B |
-60.16%
|
Dec 30, 2022 | $3.17 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
Teva Pharmaceutical Industries
TEVA
|
$24.96 B |
19.808 M
|
Israel
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Market Cap | = | AMLX Stock Price | * | AMLX Shares Outstanding |
= | $3.48 | * | 85.69 M | |
= | $0.30 B |